| Xu 2006 |
Aripiprazole: Headache: 3%, Insomnia: 3%, Sedation: 10%;Placebo: Insomnia: 13% |
_ |
| Shim 2007 |
Aripiprazole: Insomnia: 42%, Dry mouth: 31%, Headache:23%, Sedation: 12%, Weakness: 8%, Psychiatric disorder: 7.7%;Placebo: Dry mouth: 21%, Sedation: 18%, Insomnia: 18% |
Two patients in the aripriprazole group experienced insomnia, anxiety, and irritability, and both opted for withdrawal from the study. |
| Ji 2008 |
Aripiprazole: Headache: 3, Insomnia: 3, Sedation: 6;Placebo: Headache: 4, Insomnia: 5 |
Adjunctive aripiprazole vs. placebo: Subject was lost to follow-up (2 vs. 4); Switching to other antipsychotics(3 vs. 4); |
| Chen 2009 |
Aripiprazole: Dry mouth: 3, Sedation: 2, Tremor: 4, Anxiety: 4,Constipation: 6, Salivate: 8, tachycardia: 8, ALT goes up: 5, Elevatedglucose level: 3, ECG ST segment changes: 3; Placebo: Dry mouth: 3,Sedation: 3, Tremor: 4, Anxiety: 5, Tachycardia: 6, Constipation: 4,Salivate: 6, ALT goes up: 6, ECG ST segment changes: 4,Elevated glucose level: 3. |
Adjunctive aripiprazole vs. placebo: Adverse event (1 vs. 1); Subject was lost to follow-up (0 vs. 1); Switching to other antipsychotics(2 vs. 1); |
| Kane 2009 |
Aripiprazole: Fatigue: 14(8.3%), Headache: 12(7.1%), Insomnia:11(6.5%), Akathisia: 10(5.9%), Somnolence: 10(5.9%), Psychiatricdisorder: 2(1.2%), Back pain: 10(5.9%); Placebo: Fatigue:10(6.5%), Headache: 13(8.5%), Insomnia: 13(8.5%), Akathisia: 11(7.2%),Somnolence: 7(4.6%), Psychiatric disorder: 15(9.8%),Back pain: 4(2.6%) |
Adjunctive aripiprazole vs. placebo: Adverse event (5.4% vs. 10.3%); Subject withdrew consent (8.9% vs. 5.8%); Subject was lost to follow-up (7.1% vs. 7.7%); Poor/noncompliance (7.1% vs. 3.2%); Other reasons (2.4% vs. 3.9%); Lack of efficacy (0.6% vs. 0%). |
